Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt.

Next Previous
X
Search
Trial Profile

International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CLARINET
  • Sponsors Sanofi

    • Most Recent Events

    • 20 Jun 2013 Primary endpoint 'Treatment-failure-rate' has not been met.
    • 20 Jun 2013 Results published in the New England Journal of Medicine.
    • 13 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top